AMRX vs FRT · P/E 44, rev $1.52B vs rev $1.28B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus FRT (FRT) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
FRT (FRT) common stock.
Latest reported AMRX revenue for 2026-06-30 was $1.52B. Net income was $119.9M. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported FRT revenue for 2025-12-31 was $1.28B. Net income was $411.1M. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. FRT currently screens at market cap $0.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. FRT currently screens at market cap $0.
Not investment advice. Open the AMRX and FRT stock pages for the full models.
Not investment advice.